title: Immunotherapy strategies in multiple myeloma.
abstract: Multiple myeloma (MM) is a B-cell malignancy characterized by the clonal proliferation of malignant plasma cells in the bone marrow and the development of osteolytic bone lesions. MM has emerged as a paradigm within the cancers for the success of drug discovery and translational medicine. This article discusses immunotherapy as an encouraging option for the goal of inducing effective and long-lasting therapeutic outcome. Divided into two distinct approaches, passive or active, immunotherapy, which targets tumor-associated antigens has shown promising results in multiple preclinical and clinical studies.
authors.affiliation: Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA. Electronic address: Jooeun_Bae@dfci.harvard.edu.
authors.forename: Jooeun
authors.initials: J
authors.lastname: Bae
authors.affiliation: Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA.
authors.forename: Nikhil C
authors.initials: NC
authors.lastname: Munshi
authors.affiliation: Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA.
authors.forename: Kenneth C
authors.initials: KC
authors.lastname: Anderson
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006801:Humans; D007167:Immunotherapy / Q000379:methods* / Q000639:trends; D009101:Multiple Myeloma / Q000276:immunology* / Q000628:therapy*; D033581:Stem Cell Transplantation / Q000379:methods; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D059016:Tumor Microenvironment / Q000187:drug effects / Q000276:immunology
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines
keywords: Active-specific immunotherapy; Multiple myeloma; Passive-specific immunotherapy